Topic
Abbvie
Recent coverage of Abbvie from across the web.
-
Big pharma stocks close near all-time highs as tech selloff pushes investors toward safer bets
- Consumers look to salvage suit over Big Pharma price-fixing scheme
-
Investors are overlooking healthcare stocks and should consider these top picks, says JPMorgan
-
AbbVie is buying a biotech company working on an experimental eczema drug for $10.9 billion
-
AbbVie's biggest deal since 2019 could land soon
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow